Design challenges for HIV-1 vaccines based on humoral immunity

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Greenspan, Neil S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Broadly neutralizing antibody; Genomic diversity; Immune escape; Immunogen design; Non neutralizing antibody; Vaccine guided B cell evolution; Vectored immunoprophylaxis

Indexed keywords

EID: 84905642051     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00335     Document Type: Note

References (22)

1. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 58:19-42. doi: 10.1093/bmb/58.1.19
2. Burke DS. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis (1997) 3:253-9. doi:10.3201/eid0303.970301
3. Lemey P, Rambaut A, Pybus OG. HIV evolutionary dynamics within and among hosts. AIDS Rev (2006) 8:125-40.
4. Alizon S, Fraser C. Within-host and between-host evolutionary rates across the HIV-1 genome. Retrovirology (2013) 10:49. doi:10.1186/1742-4690-10-49
5. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 393:705-11. doi:10.1038/31514
6. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature (2003) 422(6929):307-12. doi:10.1038/nature01470
7. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des (2007) 13:213-27. doi:10.2174/138161207779313632
8. Chertova E, Bess JW Jr, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol (2002) 76:5315-25. doi:10.1128/JVI.76.11.5315-5325.2002
9. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grisé H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 441:847-52. doi:10.1038/nature04817
10. + regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 2:1736-46. doi:10.1016/j.celrep.2012.11.016
11. Fauci AS, Marston HD. Ending AIDS - is an HIV vaccine necessary? N Engl J Med (2014) 370:495-8. doi:10.1056/NEJMp1313771
12. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 105:7552-7. doi:10.1073/pnas.0802203105
13. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 153:126-38. doi:10.1016/j.cell.2013.03.018
14. Gitlin AD, Shulman Z, Nussenzweig MC. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature (2014) 509:637-40. doi:10.1038/nature13300
15. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med (2014) 6:236ra63. doi:10.1126/scitranslmed.3008104
16. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog (2009) 5:e1000445. doi:10.1371/journal.ppat.1000445
17. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 340:711-6. doi:10.1126/science.1234150
18. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol (1996) 157:2168-73.
19. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 23:897-906. doi:10.1097/qad.0b013e328329f97d
20. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366:1275-86. doi:10.1056/NEJMoa1113425
21. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2011) 481:81-4. doi:10.1038/nature10660
22. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med (2014) 20:296-300. doi:10.1038/nm.3471